|
|
|
|
|
|
|
21.05.25 - 09:03
|
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire EN)
|
|
|
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease (STGD1) based on the previously reported interim data from the ongoing Phase 3 DRAGON trial. There are currently no approved treatments for STGD1....
|
|
|
|
|
|
|
|
|
|
|
12.05.25 - 14:03
|
Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows:...
|
|
|
29.04.25 - 14:03
|
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting (GlobeNewswire EN)
|
|
|
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City, Utah. The presentations will highlight baseline patient characteristics from the ongoing DRAGON trial and pharmacokinetic and pharmacodynamic properties from the ongoing DRAGON II trial, both in Stargardt disease....
|
|
|
|
|
|
|
17.03.25 - 11:03
|
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire EN)
|
|
|
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 17, 2025, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C)....
|
|
|
|
|
11.03.25 - 08:03
|
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire EN)
|
|
|
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 17, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the fourth quarter and full year ended December 31, 2024....
|
|
|
27.02.25 - 08:03
|
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects (GlobeNewswire EN)
|
|
|
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need today announced that following a pre-specified Interim Analysis of the pivotal global Phase 3 “DRAGON” trial data of Tinlarebant in adolescent Stargardt disease patients, the Data Safety Monitoring Board (DSMB) has recommended the trial proceed without any modifications. The Interim Analysis was performed when all subjects completed the one-year assessment....
|
|
|
|
|
06.02.25 - 04:39
|
Belite Bio Announces Registered Direct Offering of $15 Million (GlobeNewswire EN)
|
|
|
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the purchase and sale of 258,309 American Depositary Shares (“ADSs”) and warrants to purchase 258,309 ADSs, at a purchase price of $58.07 per ADS and accompanying warrant, pursuant to a registered direct offering, equivalent to today's closing price. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses, as well as the potential for additional proceeds of approximately $15 million from the exercise of five-year warrants issued in the offering. The closing of the offering is expected to occur on or about February 7, 2...
|
|
|
|
|
23.01.25 - 11:24
|
XFRA : ICFFR - ENDE DER HANDELSUNTERBRECHUNG IN DIVERSEN AKTIEN - TEIL 2 (XETRA)
|
|
|
US00123Q1040
US00191U1025
US0021211018
US0042391096
US0050981085
US00790R1041
US0084921008
US00912X3026
US01609W1027
US0185223007
US0213691035
US0235865062
US03064D1081
US03076C1062
US0327241065
US03475V1017
US03676B1026
US03748R7474
US0375981091
US03769M1062
US03782L1017
US0423157058
US0427351004
US0534841012
US05478C1053
US05550J1016
US06652K1034
US07782B1044
US0846801076
US08862E1091
US0900401060
US09180C1062
US09239B1098
US1005571070
US1011211018
US10949T1097
US11120U1051
US1170431092
US12514G1085
US1252691001
US1272031071
US13057Q3056
US1330341082
US1331311027
US14174T1079
US15202L1070
US1550382014
US15677J1088
US1653031088
US17888H1032
US1844991018
US20786W1071
US22207T1016
US2227955026
US22658D1000
US2372661015
US2527843013
US25381B1017
US2538681030
US2561631068
US2567461080
US25754A2015
US25809K1051
US25960R1059
US26817Q8868
US2683111072
US27616P1030
US2772761019
US2810201077
US28618M1062
US28852N1090
US29414B1044
US29472R1086...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
